- Home
- MCRI vs PSNL Comparison
MCRI vs PSNL Comparison
Compare MCRI & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MCRI | PSNL |
|---|---|---|
| Founded | 1972 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | 1996 | 2019 |
Fundamental Metrics
Financial Performance| Metric | MCRI | PSNL |
|---|---|---|
| Price | $110.79 | $15.72 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 6 | 5 |
| Target Price | ★ $125.67 | $15.17 |
| AVG Volume (30 Days) | 127.0K | ★ 2.1M |
| Earning Date | 10-27-2026 | 11-04-2026 |
| Dividend Yield | ★ 1.08% | N/A |
| EPS Growth | ★ 41.41 | 33.58 |
| EPS | ★ 5.06 | N/A |
| Revenue | ★ $395,377,000.00 | $69,648,000.00 |
| Revenue This Year | $4.19 | $27.28 |
| Revenue Next Year | $2.27 | $24.60 |
| P/E Ratio | $21.94 | ★ N/A |
| Revenue Growth | ★ 114.40 | N/A |
| 52 Week Low | $88.34 | $4.96 |
| 52 Week High | $135.93 | $18.89 |
Technical Indicators
Market Signals| Indicator | MCRI | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 43.91 | 44.34 |
| Support Level | $107.39 | $15.51 |
| Resistance Level | $119.66 | $16.49 |
| Average True Range (ATR) | 3.22 | 0.24 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 40.77 | 31.97 |
Price Performance
Historical ComparisonAbout MCRI Monarch Casino & Resort Inc.
Monarch Casino & Resort Inc is engaged in providing the latest gaming, dining, and hospitality amenities. It owns and operates the Atlantis Casino Resort Spa, a hotel/casino facility in Reno, Nevada, and the Monarch Black Hawk Casino in Black Hawk. The company generates the majority of its revenue from Casinos, followed by Food & Beverage and Hotel Operations.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.